CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
vorinostat +1 moredrug
Likely dose
Not stated in record
Key inclusion· 9
  • ✓Histologically or cytologically confirmed relapsed or refractory Hodgkin lymphoma of any subtype, including lymphocyte predominant disease; must have clear evidence of disease progression or lack of response after most recent therapy
  • ✓Bidimensionally measurable disease documented within 28 days prior to registration
  • ✓Bone marrow aspirate and biopsy performed within 42 days prior to registration
  • ✓Up to 5 prior chemotherapy regimens allowed
Key exclusion· 6
  • ✕Clinical or radiographic evidence of CNS involvement by lymphoma
  • ✕Prior myocardial infarction, unstable angina, or stroke within 6 months
  • ✕HIV-positive patients, whether receiving or not receiving combination antiretroviral therapy
  • ✕Allergy to compounds of similar chemical or biological composition to vorinostat (SAHA)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00132028
NCT00132028Phase 2Completed
CompareCT.gov

A Phase II Trial of Suberoylanilide Hydroxamic Acid (NSC-701852) for Recurrent or Primary Refractory Hodgkin's Lymphoma

National Cancer Institute (NCI)·interventional·Posted Aug 19, 2005·Updated May 23, 2014

In Brief

A Phase 2 clinical trial evaluating vorinostat and laboratory biomarker analysis for Adult Favorable Prognosis Hodgkin Lymphoma and 7 related conditions. Completed, enrolled 27 participants across 1 site.

Detailed Summary

This phase II trial is studying how well vorinostat works in treating patients with relapsed or refractory advanced Hodgkin's lymphoma. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Favorable Prognosis Hodgkin Lymphoma, Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Adult Unfavorable Prognosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 19, 2005
Enrollment StartSep 1, 2005
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 20.9 years ago

Interventions

vorinostatdrug

Given orally

laboratory biomarker analysisother

Correlative studies